Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy.
To identify factors associated with cutaneous rash, we performed a retrospective multicentre analysis of HIV outpatients starting a highly active antiretroviral therapy regimen containing nevirapine. A total of 62 cutaneous adverse events were observed in 429 patients. Rash hazard was increased in women, by the prophylactic use of glucocorticoids or antihistaminics, and was reduced by escalating the initial dose of nevirapine. Women receiving glucocorticoids had a 3 month cumulative probability of rash of 0.41.
Antinori
A
A
National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy.
Baldini
F
F
Girardi
E
E
Cingolani
A
A
Zaccarelli
M
M
Di Giambenedetto
S
S
Barracchini
A
A
De Longis
P
P
Murri
R
R
Tozzi
V
V
Ammassari
A
A
Rizzo
M G
MG
Ippolito
G
G
De Luca
A
A
D000328:Adult; D018926:Anti-Allergic Agents / Q000008:administration & dosage*; D019380:Anti-HIV Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005076:Exanthema / Q000209:etiology* / Q000517:prevention & control; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D019829:Nevirapine / Q000009:adverse effects*; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D012307:Risk Factors; D012727:Sex Characteristics
D018926:Anti-Allergic Agents; D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine